Ipamorelin: A Selective GH Secretagogue That Never Crossed Into Approval

The short version

Ipamorelin is a synthetic peptide five amino acids long that acts at the ghrelin receptor (GHS-R1a) on pituitary cells to trigger a pulse of growth hormone release. Its founding characteristic, established in 1998, was that it did this without meaningfully raising cortisol or prolactin — even at doses more than 200 times its GH threshold — which made it the first growth hormone secretagogue described as selective ^[11].

Here is the honest part: ipamorelin has never been approved as a drug anywhere. Its one published Phase 2 human trial — in adults undergoing bowel surgery — missed its primary endpoint ^[8]. The dominant route of use in off-label research contexts is subcutaneous self-administration, which has no published human pharmacokinetic or safety characterization at all. Widespread clinic and online promotion for anti-aging, fat loss, or muscle gain rests largely on mechanism and short rodent studies, not on controlled human outcome trials. In 2024, the FDA removed ipamorelin from the list of bulk substances eligible for compounding ^[11]. It is also banned in competitive sport under WADA's S2 category. This page covers what the published literature actually says.

What it is

Ipamorelin (also designated NNC 26-0161 or NNC-26-0161) is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Several structural features of that sequence are pharmacologically important:

• Aib (alpha-aminoisobutyric acid) at position 1 is an unnatural alpha-methyl amino acid that resists peptidase cleavage, extending half-life.
• D-2-naphthylalanine and D-Phenylalanine are D-form (mirror-image) amino acids at positions 3 and 4, also conferring protease resistance.
• The C-terminal amide (-NH2) cap replaces the free carboxyl group, a common stability modification.

Ipamorelin was derived from GHRP-1 by removing a central Ala-Trp dipeptide; it is a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a). It is classified as a growth hormone secretagogue (GHS) — a compound that stimulates endogenous GH secretion — not a form of growth hormone itself.

How it works

Ipamorelin binds and activates the GHS-R1a receptor on pituitary somatotroph cells, which triggers a discrete pulse of growth hormone secretion. Unlike GHRH (which acts through a separate GHRH receptor), ipamorelin's mechanism is complementary and additive to the GHRH pathway — one reason it is often combined with GHRH analogues in research.

The selectivity story is its founding pharmacological feature. In rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH at doses comparable to GHRP-6 (a less selective predecessor), yet produced no significant elevation of ACTH or cortisol even at doses more than 200-fold above its GH ED50 ^[11]. This is what separates it from earlier growth-hormone-releasing peptides like GHRP-6 and GHRP-2, which did raise cortisol and prolactin substantially.

The mechanism also reaches beyond the pituitary. Ipamorelin directly stimulated insulin release from pancreatic islet tissue from both normal and streptozotocin-diabetic rats in an ex vivo preparation, via L-type calcium channels and adrenergic/cholinergic pathways — a GH-independent effect with implications for glucose handling [13 not in refs; see safety section]. GHS-R1a is also expressed on enteric and vagal neurons governing gastric motility, which was the rationale for the postoperative ileus trial, and on hypothalamic circuits involved in appetite.

What the research shows

Founding characterization (1998). In its original description, ipamorelin released GH potently across in vitro rat pituitary cells, anaesthetised rats, and conscious swine (swine ED50 = 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6), while producing no significant ACTH or cortisol elevation even at more than 200× the GH ED50 — establishing it as the first highly GH-selective secretagogue ^[11].

Human pharmacokinetics (1999). Population PK/PD modeling in healthy male volunteers given five 15-minute IV infusions of ipamorelin across dose levels from 4.21 to 140.45 nmol/kg showed dose-proportional kinetics, a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a volume of distribution at steady state of 0.22 L/kg. The GH response peaked at approximately 0.67 hours (about 40 minutes) post-dose as a single discrete pulse ^[9]. This remains one of the very few published human ipamorelin datasets and covers only acute intravenous dosing in 8 subjects per dose level.

Bone growth in rats (1999). Subcutaneous ipamorelin at 18, 90, and 450 µg/day given three times daily for 15 days dose-dependently increased longitudinal bone growth rate in adult female Sprague-Dawley rats from 42 µm/day (vehicle) to 44, 50, and 52 µm/day respectively. Notably, total IGF-1, IGF-binding proteins, and bone turnover markers did not change — suggesting the skeletal effect was driven by GH pulse amplitude rather than sustained IGF-1 elevation ^[10].

The Phase 2 trial — which failed (2014). The only published Phase 2 RCT of ipamorelin (NCT00672074) enrolled 114 adults undergoing open or laparoscopic bowel resection, with ipamorelin given IV twice daily for up to 7 days. The primary endpoint — median time to first tolerated meal — was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (P=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of placebo ^[8]. The failed endpoint is the defining fact about ipamorelin's clinical history: it reflects failed efficacy, not an incomplete program.

Chemotherapy-related weight loss in ferrets (2024). Intraperitoneal ipamorelin at 1–3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase (48–72 hours), but had no anti-emetic effect on acute or delayed cisplatin-induced emesis. A related GHS-R1a agonist, given intracerebroventricularly, reduced acute emesis by 60% — indicating the two compounds differ in central access, and ipamorelin's weight-stabilizing effect works via a peripheral mechanism ^[6].

GHS-R1a class cardiovascular signal (2015). A 28-day integrated preclinical safety study of GSK894281 — a structurally distinct GHS-R1a agonist in the same receptor class as ipamorelin — found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology, electron microscopy, and elevated serum cardiac FABP3. Ipamorelin was not the compound tested, but the finding represents a class-level cardiovascular safety signal that makes chronic systemic GHS-R1a agonism a concern in subjects with underlying cardiac vulnerability ^[7].

Muscle and body composition — preliminary (2026). A narrative review from USC Keck School of Medicine found that CJC-1295 combined with ipamorelin improved maximal tetanic tension in a murine glucocorticoid-induced muscle loss model, but concluded that evidence is limited to animal studies, safety and dosing data in humans remain unknown, and significant research is required before any clinical recommendations can be made ^[12].

Reported effects, cautions & safety

Ipamorelin has the most extensive set of community-reported signals of the three compounds on this desk, drawn from research-use forums and clinical-education sources. These are anecdotal, not clinical evidence — unverified, dose-unknown, confounded by concurrent interventions and self-selection:

Frequently reported (anecdotal):

• Deeper, more restorative sleep. Consistently the most-cited benefit in community accounts. Users describe faster sleep onset, deeper sleep architecture, and more rested mornings, often appearing within one to two weeks of pre-bed administration.
• Vivid dreams, especially in early weeks. More intense dreams commonly reported in the first one to two weeks, typically described as settling into stable deep sleep afterward.
• Faster recovery and reduced post-training soreness. Faster bounce-back between sessions, reduced muscle soreness, and improved subjective tissue recovery — including joint comfort over weeks.

Occasionally reported (anecdotal):

• Facial flushing and head-rush shortly after injection. A warm flush across the face, neck, or upper chest appearing roughly 5–15 minutes post-injection, lasting up to an hour.
• Tingling or numbness in hands and feet. Transient extremity tingling most pronounced in the first few weeks.
• Mild water retention and puffiness. Transient puffiness in fingers, ankles, or face, particularly in the first two to four weeks — described as milder than with older GHRPs.
• Increased hunger, especially after injection. Appetite increase in the hours following administration, consistent with GHS-R1a's role in ghrelin signaling and orexigenic circuits.
• Early fatigue, dizziness, or spacey feeling. Transient lightheadedness or weak sensation shortly after injecting, particularly early.
• Injection-site irritation. Localized redness, itching, or mild swelling, resolving within a day or two.
• Gradual shift toward leaner body composition. Subtle, slow changes noted from weeks five to twelve — confounded by concurrent diet and training.
• Diminishing response over months. Perceived benefits, especially sleep and GH-related sensations, reported by some users to fade after three to four months of uninterrupted use.

Key safety cautions from the literature:

• Active or recent malignancy. GH stimulates hepatic IGF-1, a characterized mitogen. Chronically raising GH-pulse amplitude is theoretically concerning in proliferative conditions. No ipamorelin-specific oncologic data exist; this is mechanistic and class-level ^[11].
• Diabetes, impaired glucose tolerance, or insulin resistance. GH is a counter-regulatory hormone that reduces peripheral insulin sensitivity. Ipamorelin also has a GH-independent insulinotropic action on pancreatic islet cells shown ex vivo. Dual metabolic influence creates unpredictable net glycemic impact in those with existing dysregulation ^[11].
• Cardiovascular disease, heart failure, or significant edema. GH excess is associated with sodium and water retention and cardiomegaly; the class-level cardiac signal from the GSK894281 study adds preclinical concern for chronic GHS-R1a agonism in those with underlying cardiac vulnerability ^[7].
• Appetite dysregulation. GHS-R1a activation drives orexigenic hypothalamic circuits. Ipamorelin also showed GH-independent adiposity and leptin elevation in mice, indicating direct ghrelin-axis adipogenic signaling beyond the GH pathway ^[6].
• Unknown long-term human safety; unverified purity. The only controlled human dataset covers short-term IV administration in at most 114 surgical patients and 8 healthy volunteers. Subcutaneous self-administration has no published human PK or safety characterization. Research-grade ipamorelin from unregulated suppliers is not subject to pharmaceutical quality assurance ^[8][9].

Where it fits on the GH-axis desk

Ipamorelin is the lead compound on this desk for one clear reason: it is the most-researched and most-discussed of the three GHS-R1a-acting, non-approved research peptides in the GH-axis category, and it illustrates the gap between mechanistic elegance and clinical validation better than almost any other peptide in the field. Its selectivity profile is genuinely well-characterized in preclinical models; its human record is thin.

Tesamorelin occupies the regulatory proof-of-concept end of the spectrum — a GHRH analogue with a real FDA approval and replicated RCT data, even if only in a specific HIV population. Together they show what compelling GH-axis pharmacology looks like at different stages of the evidence ladder. MOTS-c then extends the conversation sideways into mitochondrial signaling, where the mechanism is equally promising and the clinical evidence is even earlier. See all three on the comparison page.